Sanofi and Servier share the market of Parkinson's disease in China

Source: 21st century economic report from September 7, 2016, Servier announced that Sanofi would be fully responsible for the distribution and medical promotion of texuda, an anti Parkinson drug of Servier, in China from October 1, 2016, and signed the exclusive distribution agreement and exclusive promotion agreement The two sides worked together to establish the top experts in the field of Parkinson's disease in China“ Union against Pakistanis " For the cooperation between the two sides, Dai Chongde, general manager of Servier China, said that Sanofi's years of marketing channels in China can better promote teshuda In addition, both sides of Sanofi Servier said that the cooperation hopes to change the "three low" status of low recognition, low consultation rate and low diagnosis rate in China Media in the industry reported that several months ago, the team members of teshuda had left one after another Up to now, the remaining team of teshuda will be incorporated into other promotion teams of Servier Some industry insiders commented that it would be better to improve efficiency and ease the sales bottleneck encountered by multinational pharmaceutical enterprises if teshuda sales were entrusted to Servier It is understood that tasuda is the first non ergot dopamine receptor agonist in the world It was introduced into China by Servier in 1996, and more than one million Parkinson's patients in China use it Servier's sales in 2015 amounted to 3.9 billion euros, and the total number of employees worldwide exceeded 21000 Servier is mainly engaged in cardiovascular disease, tumor, metabolic disease, neuropsychiatric disease and rheumatism Servier invests 25% of its turnover in product research and development through its non-profit foundation For the exclusive distribution and promotion agreement signed by both parties, Dai Chongde, general manager of Servier China, said that with the strategic cooperation of Sanofi, Servier will integrate its own high-quality products and disease management resources in the field of Parkinson's disease, enrich the options of medical workers in the clinical treatment of Parkinson's disease, and improve the drug access of Parkinson's patients Both sides of Sanofi Servier said that the cooperation is to better serve Chinese patients Professor Jiang Yuping, chief physician of Neurology Department of Huashan Hospital Affiliated to Fudan University, told the 21st century economic report that the epidemiological survey in Beijing, Xi'an and Shanghai showed that the prevalence rate of Parkinson's disease among people over 65 years old was 1.7% It is estimated that the number of new patients in China each year is more than 100000 At present, there are about 2 million Parkinson's patients in China“ Parkinson's disease not only seriously affects the quality of life of patients, but also significantly increases the economic burden of patients' families According to a study, the average annual expenditure of Parkinson's disease patients on disease-related expenses accounts for 44.8% of the average annual household income " However, Parkinson's disease is still in the state of low recognition, low visit rate and low diagnosis rate in China According to reports, the treatment rate of Parkinson's disease in China is only 40%, and the diagnosis rate is only 45% "There is also a big gap between doctors in different regions in the level of diagnosis and standardized treatment of Parkinson's disease, and the effective access to high-quality treatment drugs needs to be improved." Professor Jiang Yuping, chief physician of Neurology Department of Huashan Hospital Affiliated to Fudan University, pointed out It is an indisputable fact that multinational pharmaceutical companies love and kill each other Sanofi's sales channel resources are one of the important reasons why Servier chose to cooperate with it this time Sanofi group has 11 regional branches in Beijing, Tianjin, Shenyang, Jinan, Shanghai, Hangzhou, Nanjing, Wuhan, Chengdu, Guangzhou and Urumqi, according to Peng Zhenke, general manager of Sanofi's China pharmaceutical operation, who told 21st century economic news More than employees, especially Sanofi's sales channel has sunk to county hospitals, covering more than 3000 hospitals nationwide Media in the industry reported that several months ago, the team members of teshuda had left one after another Up to now, the remaining team of teshuda will be incorporated into other promotion teams of Servier After the GSK incident, major companies began to sell and transfer their low profit and aging product lines, or cooperate with domestic pharmaceutical companies to save more money and turn to research and development of new products, and product sales are also adjusting In the past three years, the sales teams of major foreign pharmaceutical companies have also been adjusted frequently, such as the joint efforts of Servier and Sanofi to share the market, and there may be more in the future To this end, Peng Zhenke, general manager of Sanofi China pharmaceutical operation, said that there is not only fierce competition between multinational pharmaceutical companies, but also more cooperation between them In fact, as the development of traditional medicine market slows down, multinational pharmaceutical enterprises pay more and more attention to China as a high-speed developing emerging market A large number of newly developed and successfully developed drugs were introduced into China at the first time, and multinational pharmaceutical enterprises have increased their capital in China market, expanded their production bases in China, etc., and their mutual competition is self-evident